Overview

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Status:
Completed

Trial end date:
2017-06-22

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel. To determine the MTDs, patients are entered sequentially into escalating dose cohorts. Secondary objectives are objective response and disease control according to RECIST criteria version 1.1

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Albumin-Bound Paclitaxel
Exemestane
Paclitaxel